NEW YORK, United States–The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday.
Earnings per share - the benchmark for the markets - should come in at between 1.45 and 1.65 dollars, compared with 3.25 to 3.45 dollars previously anticipated."Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations," it added.
The company's shares were more than three percent lower in after hours trading at 5:30pm local time in New York .Test positivity rates, hospitalizations and deaths due to the virus are all down over the last week, according to CDC data.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Pfizer cuts earnings outlook on lower Covid-19 drug salesNEW YORK, United States - The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday.
더 많은 것을 읽으십시오 »
Pfizer cuts earnings outlook on lower Covid-19 drug salesDefining the News
더 많은 것을 읽으십시오 »